Last reviewed · How we verify
QIV Booster
At a glance
| Generic name | QIV Booster |
|---|---|
| Also known as | Fluzone® Quadrivalent |
| Sponsor | Canadian Immunization Research Network |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers (EARLY_PHASE1)
- Effects of Aging on Primary and Secondary Vaccine Responses (PHASE1)
- Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines (PHASE4)
- The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students (PHASE4)
- A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine (PHASE3)
- Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX) (PHASE2)
- CT18 Infant Influenza Priming Study in Vaccine Naive Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QIV Booster CI brief — competitive landscape report
- QIV Booster updates RSS · CI watch RSS
- Canadian Immunization Research Network portfolio CI